Trial
NCT03330418
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
RemeGen Co., Ltd.
Collaborators
—
Condition
Neuromyelitis Optica Spectrum Disorders
Intervention
Placebo
Why stopped
Sponsor Strategic Priority Adjustment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-13